MARKET

ZSAN

ZSAN

Zosano Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.350
-0.040
-2.87%
Opening 14:11 08/13 EDT
OPEN
1.360
PREV CLOSE
1.390
HIGH
1.360
LOW
1.300
VOLUME
2.42M
TURNOVER
--
52 WEEK HIGH
3.210
52 WEEK LOW
0.4050
MARKET CAP
92.59M
P/E (TTM)
-0.7405
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ZSAN stock price target is 4.333 with a high estimate of 7.00 and a low estimate of 2.000.

EPS

ZSAN News

More
Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™
Agreement outlines commercialization and distribution execution strategy upon FDA approval EVERSANA to provide commercial services of approximately $250 million over 5 yearsFREMONT, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:Z
GlobeNewswire · 6d ago
Zosano Pharma Reports Second Quarter 2020 Financial Results and Provides Corporate Update
FREMONT, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2020, as well as recent business highlights. “Zosan
GlobeNewswire · 08/06 12:00
Zosano Pharma to Present at the BTIG Biotechnology Conference 2020
FREMONT, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its president and chief executive officer, Steven Lo, will present a company overview at the BTIG Biote
GlobeNewswire · 08/03 20:05
Zosano Pharma to Showcase New Post-hoc Analyses of Qtrypta's (M207) Clinical Trial Data Comparing Key Efficacy Results From the Pivotal Study and the Open-label Long Term Safety Study on the 2020 American Headache Society's Virtual Annual Scientific Meeting Platform
Zosano Pharma Corporation (NASDAQ: ZSAN) announced Saturday that new post-hoc efficacy analyses of QtryptaTM, Zosano's lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual oral presentation on the 2020
Benzinga · 06/14 12:26
Zosano Pharma to showcase new post-hoc analyses of Qtrypta’s (M207) clinical trial data comparing key efficacy results from the pivotal study and the open-label long term safety study on the 2020 American Headache Society’s Virtual Annual Scientific Meeting Platform
Zosano Pharma Corporation (ZSAN), a clinical-stage biopharmaceutical company, today announced that new post-hoc efficacy analyses of QtryptaTM, Zosano’s lead investigational product candidate for the acute treatment of migraine, will be presented as a virtual
GlobeNewswire · 06/13 10:00
Zosano Pharma Announces Change to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
GlobeNewswire · 06/11 21:05
CHK, CPE among premarket losers
Seeking Alpha - Article · 06/09 13:14
Zosano Pharma Enters $20M Stock Sale Agreement With BTIG
Benzinga · 06/08 21:18

Industry

Biotechnology & Medical Research
+0.83%
Pharmaceuticals & Medical Research
-1.15%

Hot Stocks

Symbol
Price
%Change

About ZSAN

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.
More

Webull offers kinds of Zosano Pharma Corp stock information, including NASDAQ:ZSAN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZSAN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ZSAN stock methods without spending real money on the virtual paper trading platform.